ArticleScience translational medicine2021
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.
Open access · hybridAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 73 citations in OpenAlex.
- Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus.Science advances · 2026Article
- Article
- A TRAC-478-adjuvanted recombinant N1 neuraminidase influenza virus vaccine induces balanced and broadly protective immune responses.NPJ vaccines · 2026Article
- Exposure route drives SARS-CoV-2 infection patterns in non-human primates.bioRxiv : the preprint server for biology · 2026Article
- When less is statistically Equivalent: Lobe-Specific optimization of histopathological assessment in SARS-CoV-2 pneumonia.Computers in biology and medicine · 2025Article
- Article
- Intranasal replicon SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Intranasal replicon SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Coordinated early immune response in the lungs is required for effective control of SARS-CoV-2 replication.Nature communications · 2025Article
- Progress in combination vaccines and the co-administration of influenza virus and SARS-CoV-2 vaccines.Frontiers in immunology · 2025Review
- Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates.Nature immunology · 2024Article
- Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques.iScience · 2024Article
- Article
- Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1.Npj viruses · 2024Article
- RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination.Antiviral research · 2024Article
- Multi-compartmental diversification of neutralizing antibody lineages dissected in SARS-CoV-2 spike-immunized macaques.Nature communications · 2024Article
- Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques.Communications medicine · 2024Article
- Review
- Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2.Scientific reports · 2024Article
- Three immunizations with Novavax's protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2.NPJ vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
60 authors at 9 institutions in 4 countries.
Joseph R FrancicaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0003-1336-4682
Barbara J FlynnVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Kathryn E FouldsVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0003-4418-6495
Amy T NoeVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0002-8390-1933
Anne P WernerVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Ian N MooreVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0002-0391-6466
Matthew GagneVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0001-5526-6162
Timothy S JohnstonVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0001-9246-6155
Courtney TuckerVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Rachel L DavisVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Britta FlachVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Sarah O'ConnellVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Shayne F AndrewVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0001-7226-7757
Evan LambVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0002-6837-2842
Dillon R FlebbeVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Saule T NurmukhambetovaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Mitzi M DonaldsonVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
John-Paul M ToddVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0003-1203-3144
Alex Lee ZhuRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0003-1712-8310
Caroline AtyeoRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-7489-0232
Stephanie FischingerRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0003-2307-3379
Matthew J GormanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Sally ShinRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-9306-2264
Venkata Viswanadh EdaraCenters for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Department of Pediatrics, Atlanta, GA, 30329, USA.ORCID 0000-0001-9321-7839
Katharine FloydCenters for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Department of Pediatrics, Atlanta, GA, 30329, USA.ORCID 0000-0002-0866-6961
Lilin LaiCenters for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Department of Pediatrics, Atlanta, GA, 30329, USA.
Seyhan Boyoglu-BarnumVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Renee Van De WeteringVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0001-5330-5113
Alida TylorVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0002-0871-8151
Elizabeth McCarthyVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0002-9175-5534
Valerie LecouturierSanofi Pasteur, Marcy l'Etoile, France.ORCID 0000-0003-1580-598X
Sophie RuizSanofi Pasteur, Marcy l'Etoile, France.ORCID 0000-0002-1919-3100
Catherine BerrySanofi Pasteur, Marcy l'Etoile, France.ORCID 0000-0002-7446-0443
Timothy TibbittsSanofi Pasteur, 38 Sidney Street, Cambridge, MA 02139, USA.ORCID 0000-0002-3179-2608
Hanne AndersenBioqual Inc., Rockville, MD 20850, USA.ORCID 0000-0003-1103-9608
Anthony CookBioqual Inc., Rockville, MD 20850, USA.
Alan DodsonBioqual Inc., Rockville, MD 20850, USA.ORCID 0000-0003-2733-2753
Laurent PessaintBioqual Inc., Rockville, MD 20850, USA.ORCID 0000-0002-2126-3008
Alex Van RyBioqual Inc., Rockville, MD 20850, USA.ORCID 0000-0002-1240-9044
Marguerite KoutsoukosGSK, Wavre, Belgium.ORCID 0000-0002-4174-8424
Cindy GutzeitGSK, Rixensart, Belgium.
I-Ting TengVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Tongqing ZhouVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0002-3935-4637
Dapeng LiDuke Human Vaccine Institute, Duke University, Durham, NC 27708, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University, Durham, NC 27708, USA.ORCID 0000-0002-7643-9023
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0003-3560-232X
Adrian McDermottVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0003-0616-9117
Mark G LewisBioqual Inc., Rockville, MD 20850, USA.ORCID 0000-0001-7852-0135
Tong Ming FuSanofi Pasteur, 38 Sidney Street, Cambridge, MA 02139, USA.ORCID 0000-0003-1420-2271
Roman ChiczSanofi Pasteur, 38 Sidney Street, Cambridge, MA 02139, USA.
Robbert van der MostGSK, Rixensart, Belgium.ORCID 0000-0002-3065-6946
Kizzmekia S CorbettVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0002-2641-4688
Mehul S SutharCenters for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Department of Pediatrics, Atlanta, GA, 30329, USA.ORCID 0000-0002-2686-8380
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-7680-9215
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0001-7448-7040
Nancy J SullivanVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0002-2159-2039
Daniel C DouekVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0001-8112-0853
Danilo CasimiroSanofi Pasteur, 38 Sidney Street, Cambridge, MA 02139, USA.
Robert A SederVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA. rseder@mail.nih.gov.ORCID 0000-0003-3133-0849
National Institutes of Health · USBioqual · USRagon Institute of MGH, MIT and Harvard · USAVEO Oncology (United States) · USEmory University · USGlaxoSmithKline (Belgium) · BESanofi (France) · FRDuke University · USHarvard University · US
Funding
Non-Human Primate CoreZICAI005103 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FOULDS, KATHRYN · 2009 to 2025
$22.7MDesign Of ImmunogensZIAAI005024 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$21.5MHost Genomic Factors in Infectious Disease Susceptibility ZIAAI005066 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$17.9MThe Genome Analysis CoreZICAI005133 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2019 to 2025
$16.9MT Cell Immune Responses To HIV And Other PathogensZIAAI005033 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$11.4MThe HIV ReservoirZIAAI005034 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$7.5MInnate and Adaptive Immune Responses in SARS-CoV-2 infection (COVID-19)ZIAAI005151 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2020 to 2025
$6.8MmAbs and vaccines against SARS CoV-2ZIAAI005145 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SULLIVAN, NANCY J · 2020 to 2023
$6.2MInflammationZIAAI005031 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2024
$5.9MDesign of Antigenically-Specific Probes for Sera Analysis and MAb IsolationZICAI005111 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2010 to 2025
$4.3MImmunogen Design for SARS-CoV-2ZIAAI005149 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2020 to 2025
$2.5MDevelopment of a COVID Vaccine Model in NHPZIAAI005150 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SEDER, ROBERT A · 2020 to 2024
$2.1MAbstract
Adjuvanted soluble protein vaccines have been used extensively in humans for protection against various viral infections based on their robust induction of antibody responses. Here, soluble prefusion-stabilized spike protein trimers (preS dTM) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were formulated with the adjuvant AS03 and administered twice to nonhuman primates (NHPs). Binding and functional neutralization assays and systems serology revealed that the vaccinated NHP developed AS03-dependent multifunctional humoral responses that targeted distinct domains of the spike protein and bound to a variety of Fc receptors mediating immune cell effector functions in vitro. The neutralizing 50% inhibitory concentration titers for pseudovirus and live SARS-CoV-2 were higher than titers for a panel of human convalescent serum samples. NHPs were challenged intranasally and intratracheally with a high dose (3 × 10
Indexed as
COVID-19Spike Glycoprotein, CoronavirusAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19 SerotherapyCricetinaeImmunization, PassiveLungPrimatesSARS-CoV-2VaccinationAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.